NOVEL BIOMARKERS IN TYPE 2 DIABETES MELLITUS
DOI:
https://doi.org/10.25215/0557983827.30Abstract
Type 2 diabetes mellitus (T2DM) is a rapidly increasing metabolic disorder that is characterised by insulin resistance, chronic inflammation, and impaired insulin secretion. Conventional biomarkers such as fasting blood glucose and glycated haemoglobin (HbA1c) remain useful for diagnosis and monitoring; however, they are limited in detecting early metabolic dysfunction and predicting complications. Advances in metabolomics, proteomics, epigenetics, and microbiome research have enabled the identification of novel biomarkers that are associated with disease progression and therapeutic response. Emerging biomarkers in T2DM include inflammatory cytokines, adipokines, branched-chain amino acids, microRNAs, extracellular vesicles, hepatokines, and gut microbiome metabolites. These biomarkers may provide valuable insights into oxidative stress, endothelial dysfunction, and cardiovascular risk stratification. Advanced glycemic indicators such as glycated albumin and continuous glucose monitoring metrics have also improved the short-term glycemic assessment. Epigenetic biomarkers and circulating non-coding RNAs may support precision medicine and individualised therapy. Furthermore, biomarkers associated with nephropathy, neuropathy, and cardiovascular disease may aid early detection of complications. Although challenges remain regarding assay standardisation and validation, novel biomarkers have significant potential to improve diagnosis, prognosis, and personalised management of T2DM.Published
2026-07-03
Issue
Section
Articles
